Avi BioPharma, Inc.

Neugene maker reports loss of $0.04 per share

Published in Law and Health Weekly, December 10th, 2005

Avi BioPharma, Inc., (AVII) reported financial results for the 3 and 9 months ended September 30, 2005.

The net loss for the third quarter of 2005 was $1.7 million, or $0.04 per share, compared with a net loss of $5.1 million, or $0.14 per share, for the third quarter of 2004. Revenues for the 2005 third quarter were approximately $3.3 million, primarily due to the recognition of $3.2 million in research contract revenue from the receipt of $3.4 million in government funding for work on viral disease research projects and higher grant revenues. This compares with revenues of approximately $9,000 in the prior-year third quarter.

Research and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2005-12-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry